Mesdopetam (IRL790) is a dopamine D3 receptor antagonist with a Ki of 90 nM and an IC50 of 9.8 μM for the human recombinant D3 receptor. It exhibits psychomotor stabilizing properties and is utilized in the study of motor and psychiatric complications associated with Parkinson's disease.

Mesdopetam (IRL790) (3.7, 11, 33, or 100 μmol/kg) dose-dependently inhibits the behavioral activation following pretreatment with D-amphetamine or MK-80[1]. Mesdopetam (10 mg/kg; intraperitoneally; fourteen-week-old male C57BL/J mice) promotes a sedative effect similar to haloperidol with significantly reduced total distance traveled and reduced average speed[2]. Animal Model: Male Sprague-Dawley rats[1]Dosage: 3.7, 11, 33, or 100 μmol/kg (synthesized in-house as HCl salt, was dissolved in physiologic saline (0.9% w/v NaCl) Administration: s.c. was administered subcutaneously 4 min before the start of recording Result: Dose-dependently inhibited the behavioral activation following pretreatment with D-amphetamine or MK-801.